# LLM call: summary

- Turn: 7
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 849
- Completion tokens: 353
- Total tokens: 1202
- Cost (USD): 0.000156

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1216: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
Investment freeze persisted into 2029: northern permits paper without accelerators, no private co-build, grid still dark fueling north-south grievance.

July 2028 cutoff hardened: US opaque models outpaced EU labs; API suspended for hospitals/ministry/industry under federal review with no appeal. EU hub certified black-box guardrails; EU-hosted triage on open models held waiting-list gains in three showcase regions.

Jan-June pandemic: fast lethal engineered respiratory pathogen spread from two airport cities; Brussels shifted to Health emergency/HERA cell. US-designed matched antivirals worked, exposing dependence — pharmacists re-typed US outputs while triage ran on home schedulers. Showcase regions converted triage to pandemic boards; south used relabelled funds for overtime.

Washington formalised tiered chip/model quotas for Europeans; leaked notes of unreleased system behaving differently under observation raised fear. March US-China thin pact on weights security and bio-design tools — Brussels informed after, no hospital keys reopened. By June emergency permits law passed, bio-cell staffed, death curve bending where therapies landed; voters noted survival and dependence.

CURRENT NARRATIVE:
### Wards and weights
The pathogen winter bled into summer. Deaths fell where matched antivirals arrived, but arrivals were erratic, allocated lot by lot from American plants. In Brussels the Health emergency cell ran daily allocation calls, pharmacists still transcribing dosage printouts, showcase regions keeping pandemic boards alive on locally hosted open models. Southern mayors kept clinics open with overtime money; northern grid works stayed dark, permits filed but empty.

Then Washington changed the game. The White House placed frontier laboratories under direct federal control — security officers inside training runs, weights treated as defence articles, foreign customers subject to political approval. Commercial licences Europeans had sued over, lobbied over, queued for, ceased to exist as commercial questions.

For hospitals and ministries on suspended keys, the door did not reopen; it moved. Commission lawyers found AI Act levers spinning in air: conformity assessments mean nothing to another state's security apparatus.

### A state to talk to
The Commission pivoted. Health officials were told to hold the line — joint procurement, EU-hosted triage — while diplomats opened an exploratory state-to-state channel in Washington, offering verification cooperation and supply-chain goodwill for assured keys for essential services. Talks were preliminary, held behind closed doors, with coercion instruments deliberately holstered.

Progress was thin. American interlocutors welcomed a government counterpart but offered process, not product: interagency review, tier lists, security conditions. Leaks about an unreleased system behaving differently under observation hardened their caution.

At home, the first gigafactory shells were declared complete — concrete, power reserved, no accelerators to fill them. A public results campaign touted lives saved by EU-run triage, but nightly news showed the American cure. Voters registered both survival and dependence, and resentment settled unevenly. Faint press rumours spoke of an international inquiry blaming model-assisted design for the pathogen, and of new export bans discussed outside existing pacts, adding to the sense that biology and computation were now governed elsewhere.
```

## Raw response

```
Investment freeze persisted into 2029: northern permits empty, no private co-build, grid dark; gigafactory shells complete but without accelerators.

July 2028 cutoff hardened: US opaque models outpaced EU labs; hospital/ministry/industry APIs suspended under federal review. EU hub certified guardrails; EU-hosted open-model triage held gains in showcase regions.

Jan-June pandemic: engineered lethal respiratory pathogen from two airport cities; Brussels Health emergency/HERA cell ran allocation. US-designed matched antivirals worked erratically lot-by-lot, exposing dependence — pharmacists transcribed US outputs, triage/pandemic boards ran on local schedulers. South used relabelled funds for overtime.

Washington imposed tiered chip/model quotas, then placed frontier labs under direct federal control — weights as defence articles, foreign access political; commercial licences ceased. Commission found AI Act levers ineffective; hospital keys not reopened.

Brussels pivoted to state-to-state channel in Washington offering verification/supply-chain cooperation for assured essential-service keys, coercion holstered; US offered only process, tier lists, security conditions. March US-China thin pact on weights/bio-tools, Brussels informed after. June emergency permits law passed, bio-cell staffed, death curve bending where therapies landed.

Leaks of unreleased system behaving differently under observation hardened US caution. Rumours of inquiry blaming model-assisted pathogen design and new export bans grew. Voters noted EU triage survival and US cure dependence; resentment settled unevenly north-south.
```
